Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tuvusertib (M1774) Monotherapy and in Combination With Niraparib in Advanced Solid Tumors
NCT04170153Phase 1Active, not recruiting
- Sponsor
- EMD Serono
- Start
- Dec 2019
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of tuvusertib in solid tumor (6 arms), sponsored by EMD Serono. Primary endpoints: Dose-Limiting Toxicities, Treatment-emergent Adverse Events and 6 more. Started Dec 2019; status: active, not recruiting.
02
Drugs
tuvusertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04170153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04170153.